Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
PATTERN-studie voor therapie op maat bij stadium II coloncarcinoom
sep 2021 | Maag-darm-leveroncologie